COSM Quote, Financials, Valuation and Earnings

Gold Entertainment Group, Inc. has a net margin of -31.29% compared to Cosmos Health, Inc.'s net margin of --. Cosmos Health, Inc.'s return on equity of -68.76% beat Gold Entertainment Group, Inc.'s return on equity of --.

Cosmos Health, Inc. has a consensus price target of $3.00, signalling upside risk potential of 466.04%. On the other hand Gold Entertainment Group, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cosmos Health, Inc. has higher upside potential than Gold Entertainment Group, Inc., analysts believe Cosmos Health, Inc. is more attractive than Gold Entertainment Group, Inc..

Cosmos Health, Inc. has a beta of 4.381, which suggesting that the stock is 338.129% more volatile than S&P 500. In comparison Gold Entertainment Group, Inc. has a beta of 22.515, suggesting its more volatile than the S&P 500 by 2151.46%.

Cosmos Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gold Entertainment Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmos Health, Inc. pays -- of its earnings as a dividend. Gold Entertainment Group, Inc. pays out -- of its earnings as a dividend.

Cosmos Health, Inc. quarterly revenues are $17.1M, which are larger than Gold Entertainment Group, Inc. quarterly revenues of --. Cosmos Health, Inc.'s net income of -$5.4M is higher than Gold Entertainment Group, Inc.'s net income of --. Notably, Cosmos Health, Inc.'s price-to-earnings ratio is -- while Gold Entertainment Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmos Health, Inc. is 0.24x versus 6.01x for Gold Entertainment Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -31.29% compared to Cosmos Health, Inc.'s net margin of -162.05%. Cosmos Health, Inc.'s return on equity of -68.76% beat Standard BioTools, Inc.'s return on equity of -24.44%.

Cosmos Health, Inc. has a consensus price target of $3.00, signalling upside risk potential of 466.04%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could fall by -7.74%. Given that Cosmos Health, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Cosmos Health, Inc. is more attractive than Standard BioTools, Inc..

Cosmos Health, Inc. has a beta of 4.381, which suggesting that the stock is 338.129% more volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.

Cosmos Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmos Health, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

Cosmos Health, Inc. quarterly revenues are $17.1M, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. Cosmos Health, Inc.'s net income of -$5.4M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, Cosmos Health, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmos Health, Inc. is 0.24x versus 4.94x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Yijia Group Corp. has a net margin of -31.29% compared to Cosmos Health, Inc.'s net margin of 8.38%. Cosmos Health, Inc.'s return on equity of -68.76% beat Yijia Group Corp.'s return on equity of 55.22%.

Cosmos Health, Inc. has a consensus price target of $3.00, signalling upside risk potential of 466.04%. On the other hand Yijia Group Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Cosmos Health, Inc. has higher upside potential than Yijia Group Corp., analysts believe Cosmos Health, Inc. is more attractive than Yijia Group Corp..

Cosmos Health, Inc. has a beta of 4.381, which suggesting that the stock is 338.129% more volatile than S&P 500. In comparison Yijia Group Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cosmos Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yijia Group Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmos Health, Inc. pays -- of its earnings as a dividend. Yijia Group Corp. pays out -- of its earnings as a dividend.

Cosmos Health, Inc. quarterly revenues are $17.1M, which are larger than Yijia Group Corp. quarterly revenues of $427.1K. Cosmos Health, Inc.'s net income of -$5.4M is lower than Yijia Group Corp.'s net income of $35.8K. Notably, Cosmos Health, Inc.'s price-to-earnings ratio is -- while Yijia Group Corp.'s PE ratio is 46.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmos Health, Inc. is 0.24x versus 14.42x for Yijia Group Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Zynex, Inc. has a net margin of -31.29% compared to Cosmos Health, Inc.'s net margin of -321.21%. Cosmos Health, Inc.'s return on equity of -68.76% beat Zynex, Inc.'s return on equity of -709.17%.

Cosmos Health, Inc. has a consensus price target of $3.00, signalling upside risk potential of 466.04%. On the other hand Zynex, Inc. has an analysts' consensus of $3.70 which suggests that it could grow by 1827.08%. Given that Zynex, Inc. has higher upside potential than Cosmos Health, Inc., analysts believe Zynex, Inc. is more attractive than Cosmos Health, Inc..

Cosmos Health, Inc. has a beta of 4.381, which suggesting that the stock is 338.129% more volatile than S&P 500. In comparison Zynex, Inc. has a beta of 0.987, suggesting its less volatile than the S&P 500 by 1.301%.

Cosmos Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zynex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmos Health, Inc. pays -- of its earnings as a dividend. Zynex, Inc. pays out -- of its earnings as a dividend.

Cosmos Health, Inc. quarterly revenues are $17.1M, which are larger than Zynex, Inc. quarterly revenues of $13.4M. Cosmos Health, Inc.'s net income of -$5.4M is higher than Zynex, Inc.'s net income of -$42.9M. Notably, Cosmos Health, Inc.'s price-to-earnings ratio is -- while Zynex, Inc.'s PE ratio is 18.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmos Health, Inc. is 0.24x versus 0.06x for Zynex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.